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Abstract
Background: Thiadiazolidinones (TDZD) are small heterocyclic compounds first described as non-ATP competitive inhibitors
of glycogen synthase kinase 3b (GSK-3b). In this study, we analyzed the effects of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-
3,5-dione (TDZD-8), on murine GL261 cells growth in vitro and on the growth of established intracerebral murine gliomas in
vivo.
Methodology/Principal Findings: Our data show that TDZD-8 decreased proliferation and induced apoptosis of GL261
glioblastoma cells in vitro, delayed tumor growth in vivo, and augmented animal survival. These effects were associated with
an early activation of extracellular signal-regulated kinase (ERK) pathway and increased expression of EGR-1 and p21 genes.
Also, we observed a sustained activation of the ERK pathway, a concomitant phosphorylation and activation of ribosomal S6
kinase (p90RSK) and an inactivation of GSK-3b by phosphorylation at Ser 9. Finally, treatment of glioblastoma stem cells
with TDZD-8 resulted in an inhibition of proliferation and self-renewal of these cells.
Conclusions/Significance: Our results suggest that TDZD-8 uses a novel mechanism to target glioblastoma cells, and that
malignant progenitor population could be a target of this compound.
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Introduction
Glioblastomas (GBM) are the most frequent and aggressive
neoplasm among human primary brain tumors [1]. Despite many
efforts to overcome this aggressive disease the median survival of
patients with GBM remains less than 12 months from the time of
diagnosis [1,2]. Advances in glioma modeling in the mouse have
made the disease amenable to in vivo functional and molecular
studies [3]. Although there have been important advances in our
understanding of malignant gliomas and progress in treating them,
the mechanisms underlying GBM pathogenesis and poor response
to conventional therapy are yet unclear.
GSK-3b is a serine/threonine kinase which activity is regulated
by site-specific phosphorylation. Full activity of this enzyme
generally requires phosphorylation at Tyr-216, and conversely,
phosphorylation at Ser-9 inhibits GSK-3b activity. Different
studies have shown that GSK-3b is involved in many biological
processes, including cell cycle progression, apoptosis and viability,
cytoskeletal organization, cellular metabolism and tumorigenesis
[4,5]. Several of these pathways, are implicated in disease
pathogenesis, which has prompted efforts to develop GSK-3b
inhibitors for therapeutic applications. GSK-3b plays an impor-
tant role in glucose metabolism and it is thought to facilitate the
development of non-insulin-dependent diabetes [6]. Also, GSK-3b
has an important role in promoting inflammatory processes
through its activation of the transcription factor NF-kB [7]. This
kinase has also been implicated in the development of Alzheimer
disease and other neurodegenerative disorders [8]. Lastly, several
studies have identified a specific role for GSK-3b on proliferation
and apoptosis of cancer cells. GSK-3b activation has been
associated with prostate cancer progression [9], and inactivation
of this enzyme activates a p53-dependent apoptosis pathway
resulting in a diminished colorectal cancer cell growth [10].
The thiadiazolidinone compound TDZD-8 belongs to a family
of molecules, which was originally described as non-ATP
competitive inhibitors of glycogen synthase kinase 3b (GSK-3b)
[11,12]. In line with the implication of GSK-3b-activated
pathways in disease pathogenesis, TDZD-8 has been shown to
be a protective agent in multiple murine models of disease such as
arthritis, spinal cord injury, colitis, and septic shock
[13,14,15,16,17]. More recently, TDZD-8 has been shown to
selectively induce death of several major forms of leukemia cells,
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including malignant myeloid stem and progenitor populations,
while sparing normal hematopoietic tissue [18].
In an effort to expand strategies for targeting glioblastoma cells, we
have explored the effects of TDZD-8 on glioblastoma development.
We demonstrate that TDZD-8 is a potent anti-proliferative and pro-
apoptotic agent of glioma cells in vitro and in vivo. These effects are
associated with an early activation of extracellular signal-regulated
kinase (ERK), which is followed by an increased expression of the
early growth response-1 (EGR-1) and p21. TDZD-8 also elicited a
sustained activation of ERK which lead to a phosphorylation of
p90RSK and a concomitant inhibition of GSK-3b through
phosphorylation of Ser-9. We also demonstrate that TDZD-8
inhibits the growth and neurosphere formation and self-renewal
capacity of GL261 cells. As such, these findings identify TDZD-8 as a
potential therapeutic agent for the treatment of high grade gliomas.
Results
TDZD-8 treatment reduces glioblastoma development in
vivo
To analyze the effects of TDZD-8 on glioblastoma growth in vivo,
we orthotopically implanted GL261 glioma cells into adult mice
brains to generate tumors. The murine glioma GL261 model has
been the most common used syngeneic transplant model for both
subcutaneous and intracranial experimental glioma tumors
[19,20,21]. This particular intracranial animal model recapitulates
many of the histopathological and biological features of human
glioma including necrosis with pseudopalisading, blood vessels
infiltration and presence of giant multinucleated cells [22]. First, we
monitored tumor growth in vivo by magnetic resonance imaging
(MRI) at different times after implantation. Animals treated with
TDZD-8 1 day after GL261 cell implantation showed a delayed
onset and progression of tumors compared to control animals
(Fig. 1A, B). Also, tumor volume, as assessed by T1-weighed images
after gadolinium contrast administration, was significantly reduced
in mice treated with TDZD-8 (Fig. 1A). About 84% reduction in
tumor volume was observed in tumors derived from TDZD-8-
treated animals at 13 days post-injection (Fig. 1C). This strong
reduction in the tumor growth potential induced by the compound
was also observed 20 days post-injection. Both the log-rank test and
Kaplan-Meier analysis of the survival data demonstrated a
significant survival advantage for the mice treated with TDZD-8
when compared to their controls (40 versus 30 days) (Fig. 1D). Log-
rank analysis of the data yielded a p value of 0.006. Of note, this
delayed tumor growth was also detected when the TDZD-8
treatment was started 6 days after GL261 cell injection (Fig. S1).
We next performed histological examination of tumor tissues 12
and 24 days after treatment (Fig. 2A). Microscopically all the
tumors were made of sheets of malignant cells that leaved some
microcysts among them. These cells showed highly atypical nuclei
with prominent nucleoli and an eosinophilic cytoplasm with
filamentous elongations. Many multinucleated malignant cells
were also seen (Fig. 2A, asterisks in insets). Altogether these
features are characteristic of a typical human high-grade glioma.
The grade of pleomorphism and nuclear atipia and the mitotic
activity were reminiscent of that found in human glioblastoma
multiforme. Tumors from control animals presented more mixoid
matrices (Fig. 2A, arrows in insets) and a higher mitotic activity
with more than 5 mitotic figures per high power field (Fig. 2A,
arrowheads in insets), as compared with TDZD-8-treated animals.
To further understanding on tumors characteristics we per-
formed PCNA and active caspase-3 immunohistochemistry 12 days
after implantation to assess the effect of TDZD-8 on proliferation
and apoptosis. Quantification of the data revealed that TDZD-8-
treated animals showed a significant reduction of PCNA expression
(Fig. 2B), suggesting a growth-suppressing action of this compound
in vivo. Figure 2B also shows that mice treated during 12 days with
TDZD-8 presented tumors with elevated active caspase-3 expres-
sion, compared with vehicle-treated animals, indicating that
TDZD-8 promoted apoptosis of glioma cells in vivo.
TZDZ-8 decreases cell proliferation and survival in vitro
To understand the mechanism by which TDZD-8 inhibits tumor
growth, we initially tested its antiproliferative effect on GL261
glioblastoma cells analyzing BrdU incorporation. Exponentially
growing GL261 cells were exposed to 20 mM TDZD-8 for 24 and
48 h, and their proliferation was monitored. A significant decreased
in proliferation was observed in cells treated for both 24 and 48 h
with 20 mM TDZD-8 compared with untreated control cells
(Fig. 3A). Additionally, cell viability, measured by the MTT assay,
was significantly diminished in TDZD-8-treated cells (Fig. 3B),
compared to controls. Thus, TDZD-8 has an antiproliferative effect
on GL261 glioblastoma cells. This anti-proliferative effect of
TDZD-8 was also observed in other two human glioblastoma cell
lines, A172 (Fig. 3C, D) and U373 (Fig. 3E, F).
To further investigate the role of TDZD-8 in cell growth
inhibition, cell death was evaluated by active caspase-3 and
TUNEL analysis (Fig. 4). Treatment of GL261 cells at different
times with TDZD-8 resulted in an increase of apoptosis that was
evident by an increase in the abundance of cleaved caspase-3
(Fig. 4A). Yet again, this proapoptotic effect was also observed in
the A172 and U373 glioma cell lines. TUNEL analysis of GL261
cells showed a significant increase in the number of apoptotic cells
after TDZD8 treatment (Fig. 4C). Addition of the caspase
inhibitor N-benzoylcarbanyl-Val-Ala-Asp-fluoro methylketone
(zVAD-fmk) inhibited TDZD-8-induced caspase activation and
cell death (Fig. 4B, C). Altogether, these results indicate that
TDZD-8 treatment led to a growth arrest of glioblastoma cells by
a diminution of cell proliferation and an induction of apoptosis.
Effects of TDZD-8 on the mitogen-activated protein
kinase (MAPK) pathway and NF-kB activation
We next investigated possible signaling pathways involved in the
TDZD-8 anti-proliferative effects on glioblastoma cells. Activation
of ERK has been associated with a diminution of cell survival in
different tumor cell lines, including glioblastoma cell lines
[23,24,25]. Therefore, we next investigated the possible involve-
ment of this pathway in the anti-proliferative and pro-apoptotic
effects of TDZD-8 described here. First, we evaluated the
phosphorylation status of ERK1/2. As can be seen in Figure 5A,
ERK1/2 become rapidly phosphorylated after TDZD-8 treatment.
Next, we examined the expression of two genes known to play an
important role in cell growth and which are downstream targets of
the ERK cascade [26], the early growth response -1 (EGR-1) gene
and p21. An increase in the expression of both genes was observed 1
and 2 hours after TDZD-8 addition to GL261 cells (Fig. 5A). In
addition to this rapid effect, we also detected a sustained activation
of ERK1/2 and a sustained increase of p21 (Fig. 5B, C). Since the
ribosomal S6 kinase (p90RSK) is a well-known target of ERK
[27,28] and activated p90RSK can inactivate GSK-3b by
phosphorylation at Ser9, we then analyzed the effect of TDZD-8
treatment on the phosphorylation status of these enzymes. As shown
in Figure 5B an increase in phosphorylation of p90RSK at Ser380
and GSK-3b at Ser9 was detected 24 hours after TDZD-8
treatment. Noteworthy, although the increase in phosphorylation
of ERK1/2 is not as high as the one observed at shorter time points
(Fig. 5A) this enhancement is consistent and sufficient to initiate the
signaling cascade leading to activation of their target p90RSK and
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subsequent inactivation of GSK-3b. To further substantiate the
notion that the ERK/p90RSK pathway is involved in the
phosphorylation of GSK-3b after TDZD-8 treatment, we used
the PD98059 inhibitor to block this pathway. Our results show that
addition of PD98059 significantly inhibited the phosphorylation of
GSK-3b at Ser9, suggesting that activation of the ERK pathway
plays a major role in the phosphorylation and concomitant
inactivation of this enzyme [29].
Since it has been also shown that GSK-3b regulates tumor cell
survival through a NF-kB-dependent pathway [7,30] we next
tested whether GSK-3b inhibition by TDZD-8 could affect NF-kB
activity in GL261 cells. To this end, we performed transient
Figure 1. Effects of TDZD-8 treatment on tumor growth in vivo. (A) Representative T1 magnetic resonance imaging (MRI) pictures obtained form
mice injected with GL261 and treated with TDZD-8 (5 mg/Kg). T1-weighted imaging was performed at 7 Tesla as described in Materials and Methods at
different times after injection. (B) Representative photographs of GL261 tumors 24 days after implantation are shown. (C) Quantitative analysis of total
tumor volumes. Values represent the mean6 SD from five different animals. (D) Kaplan-Meier plots and log-rank statistics analysis of overall survival reveal
that TDZD-8 treatment significantly improves survival of tumor-bearing mice compared with their non-treated controls (log-rank test p= 0.006).
doi:10.1371/journal.pone.0013879.g001
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Figure 2. Histological and immunohistochemical analysis of tumors induced by GL261 glioblastoma cells. (A) Representative
hematoxylin-eosin stained sections of tumors at 12 and 24 days after injection. Insets show higher magnifications of images shown in the upper
panels. Tumors derived from control animals showed clear mixoid matrices (arrows), multinucleated malignant and pleomorphic cells (asterisks), and
numerous mitotic figures (arrowheads). (B) Immunohistochemical study of tumor sections for PCNA and active caspase-3 detection 12 days after
injection of GL261 cells. Insets show a higher magnification of the images shown in the upper panels. Scale bars, 300 mm. Insets scale bars, 25 mm.
Quantification of the number of active caspase-3 and PCNA positive cells was evaluated in tumor sections and values expressed as mean 6 SD.
positive cells/field. ***p#0.001.
doi:10.1371/journal.pone.0013879.g002
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transfection assays using a reporter construct that contains three
copies of the consensus NF-kB response element (3xKBtk-luc) to
determine NF-kB activity in control and TDZD-8-treated cells. As
shown in Figure 5D, TDZD-8 inhibited NF-kB activity, which is
in accordance with previously published data [31,32].
Effect of TDZD-8 on glioblastoma stem cells
The emerging cancer stem cell model suggests that tumors are
organized in a hierarchy with a subpopulation of cancer stem cells
(CSCs) responsible for tumor maintenance and progression.
Therefore, we determined whether TDZD-8 could also exert an
Figure 3. Effect of TDZD-8 treatment on cell proliferation and survival in different glioblastoma cell lines. GL261 (A, B), A172 (C, D) and
U373 (E, F). (A, C, E) Proliferation rates determined by a BrdU incorporation assay. Tumoral cells were seeded into individual wells of a 96-well plate
and cultivated for 24 and 48 h in the presence or absence of TDZD-8 after which BrdU was added to the culture medium. Cells were harvested 16 h
after BrdU addition. Indicated are the means 6 SD measured. (B, D, F) Cells were seeded in a 96-well plate and at different times after plating cell
viability was determined by the MTT assay, as indicated in Materials and Methods. Values are the means 6 SD of at least three different experiments.
doi:10.1371/journal.pone.0013879.g003
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Figure 4. Effect of TDZD-8 treatment on apoptosis. (A) Different glioblastoma cell lines were grown on glass coverslips, treated with TDZD-8
for different times and active caspase-3 was analyzed by immunofluorescence using a specific anti-active caspase-3 antibody. (B) GL261 glioblastoma
cells were grown for 24 h on glass coverslips, treated with TDZD-8 or TDZD-8 plus zVAD-fmk and active caspase-3 was analyzed by
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antiproliferative effect on progenitor glioblastoma stem cells by
analyzing its effect in GBM-derived neurospheres. It has been
shown that the major intermediate filament protein Nestin could
be used as a marker of brain CSCs as well as normal neural stem
and precursor cells [33,34,35,36]. Therefore, as a first step to
establish if TDZD-8 could affect the CSC population in GL261
glioblastoma cells, we examined its effect on the expression of
Nestin in adherent cultures of GL261 cells. The results shown in
Figure 6A reveal a significant reduction in the protein levels of
Nestin in those cultures treated with TDZD-8, which could
Figure 5. TDZD-8 activates the ERK signaling pathway. (A, B) GL261 cells were treated or not with TDZD-8 for different times and then stained
with the corresponding primary antibodies. Some cultures were pretreated for 1 h with the ERK inhibitor PD98059. (C) Quantification of the kinetic
induction of p21 by TDZD8. (D) A reporter assay was performed to measure the transcriptional activity of NF-kB. GL261 cells were transfected with
3xNF-tk-luc reporter construct for 48 h in the presence or absence of TDZD-8 and luciferase activity was measured.
doi:10.1371/journal.pone.0013879.g005
immunofluorescence using a specific anti-active caspase-3 antibody. Scale bar, 25 mm. (C) GL261 glioblastoma cells were grown for 24 h on glass
coverslips, treated with TDZD-8 or TDZD-8 plus zVAD-fmk and TUNEL analysis was performed. Representative immunofluorescence images are
shown. Scale bar, 25 mm. Quantification of TUNEL-positive cells 24 h after TDZD-8 treatment is shown in the right panel. B, basal non-treated cells.
Values are the means 6 SD of at least three different experiments.
doi:10.1371/journal.pone.0013879.g004
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indicate a loss of stem cells induced by this compound. To further
elucidate this point, we examined the effects of TDZD-8 on the
formation and growth of GL261-derived neurospheres (primary
neurospheres). First, we analyzed the levels of two well-known
stem cell markers such as musashi-1 and oct-4 in adherent GL261
cells and neurosphere cultures. As shown in Figure 6B an
increased amount of these proteins was observed in the neuro-
spheres indicating an increased population of stem cells in these
cultures, compared with attached GL261 cells. Next, we studied if
TDZD-8 could affect the CSC population in GL261 glioblastoma
cells. Figure 6C shows that TDZD-8 inhibited the formation of
primary neurospheres. We observed a significant decrease, at both
7 and 14 days of culture, in the number and volume of TDZD-8-
treated neurospheres, compared with controls. To more strin-
gently test the effect of TDZD-8 on the ability of GBM cells to
generate new spheres, actively growing 7 day-old GL261-derived
primary neurosphere cultures were dissociated, and equal
numbers of viable cells were replated in fresh neurosphere
medium to generate new neurospheres (secondary neurospheres).
Treatment of these cultures with TDZD-8 almost completely
blocked the formation of secondary neurospheres (Fig. 6D).
Additionally, when primary TDZD-8-treated cultures were
dissociated and cultured again for 7 days in the absence of
TDZD-8, no formation of secondary neurospheres was observed
(data not shown). Finally, to test for the effect of TDZD-8 on the
self-renewal of the neurosphere cultures, we dissociated established
7 day-old primary neurosphere cultures, plated them at a very low
density [37], and analyzed the capacity to form secondary spheres.
As shown in Figure 6E cultures treated with TDZD-8 did not give
rise to secondary neurospheres 7 and 14 days after plating,
indicating that these cultures did not contain self-renewing stem
cells.
Figure 6. Effect of TDZD-8 on neurosphere formation. (A) Representative Western blot showing Nestin expression in adherent GL261 cells treated
with TDZD-8. (B) Representative Western blot of stem cells markers musashi-1 and oct-4 in adherent GL261 and neurospheres cultures 7 days after plating.
(C) Representative microphotographs of primary neurosphere cultures 7 and 14 days after plating in neurosphere medium. D) Primary neurospheres were
dissociated and plated to analyze secondary neurosphere formation. Representative microphotographs are shown. (E) Representative microphotographs
showing self-renewal capacity of neurosphere cultures growing in the presence or absence of TDZD-8. Scale bar, 100 mm.
doi:10.1371/journal.pone.0013879.g006
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Discussion
In this study, we show for the first time that TDZD-8 suppresses
the growth of glioma tumors in vivo and exerts anti-proliferative and
pro-apoptotic activities in glioma cells in vitro. These effects were
accompanied by an activation of the ERK/p90RSK pathway, a
concomitant phosphorylation and inactivation of GSK-3b, and an
inhibition of NF-kB activity. Finally, our data showing that TDZD-
8 decreases the formation of neurospheres, both at low and high cell
density, suggest that this drug could have an inhibitory effect on
glioblastoma stem cells proliferation and self-renewal. Collectively,
our findings suggest that TDZD-8 might be of therapeutic
importance for the treatment of high-grade gliomas.
Previous studies have implicated GSK-3b in tumorigenesis.
GSK-3b activation has been associated with prostate cancer
progression and TDZD-8 has an inhibitory effect in these tumor
cells [9]. Also, GSK-3b inactivation induces a p53-dependent
apoptotic pathway resulting in a diminished colorectal cancer cell
growth [10,38]. More recently, it has been shown that TDZD-8
inhibits proliferation and induces death of myeloma cell lines [39]
and of malignant myeloid progenitors, while sparing normal
hematopoietic tissue [18]. In the case of tumors from the central
nervous system, contradictory results have been reported.
Kotliarova et al. using different glioma cell lines have shown that
GSK-3b activation promotes cell survival [30], whereas Ma et al.
[40] have shown that GSK-3b activation is required for the
induction of apoptosis in SK-N-MC neuroblastoma cells. Our data
are in agreement with the results obtained by Kotliarova et al, here
we clearly show that the inactivation of GSK-3b by TDZD-8
inhibits glioblastoma tumor growth in vivo. Thus, tumor
development was significantly delayed and animal survival
improved (p=0.006) in mice injected with this compound.
Moreover, TDZD-8 tumors lacked the aggressiveness of control
tumors, including necrotic foci and a higher mitotic activity.
In view of the pleiotropic effects of TDZD-8, it is very likely that
different mechanisms can be underlying its action. Initially
TDZD-8 was synthesized as a high affinity ATP-non-competitive
inhibitor of GSK-3b [11,12]. However, recently, several lines of
evidence indicate that a GSK-3b-independent mechanism may be
involved in TDZD-8 actions. Guzman et al have suggested that
the activity of TDZD-8 can be independent of this inhibition since
other known GSK-3b inhibitors fail to induce leukemia-specific
cell death [18]. In this regard, we have shown that other TDZD
compounds exert anti-inflammatory and neuroprotective effects in
the brain through activation of the nuclear receptor PPARc
[41,42]. Here, we show that TDZD-8 rapidly activates ERK
signaling pathway, which promotes EGR1 expression and an
increase in p21 levels. Given the fact that this activation is very
fast, it is very unlikely that it could be mediated trough activation
of PPARc. Our findings further corroborate other studies showing
that an activation of MAPK signaling pathway in U-87MG glioma
cells leads to a proliferation arrest mediated by an increase in
EGR-1 expression which concomitantly stimulates p21 transcrip-
tion [26]. In addition, we also show a delayed activation of ERKs
in response to TDZD-8, which is followed by a phosphorylation
and activation of p90RSK, a well-known target of these kinases
[27,28]. This activation results in a phosphorylation and
inactivation of GSK-3b [29]. These results are in agreement with
previously published data showing that an activation of ERK is
associated with a diminution of cell survival in different tumor cell
lines, including glioblastoma cell lines [23,24,25]. Our results
therefore suggest that TDZD-8 can inhibit GSK-3b activity not
only by directly interacting with this enzyme but also through its
phosphorylation at Ser9 via MAPK pathway activation.
It has been reported that inhibition of GSK-3b by different
compounds, including TDZD-8, causes an inactivation of NF-kB
activity [31,32] and Kotliarova et al have shown that several small
molecular inhibitors of GSK-3b activity inhibit glioma cell survival
in part through a decrease in intracellular NF-kB activity [30].
Consistent with these data we also show here that treatment of
GL261 glioma cells with TDZD-8 led to a decrease in NF-kB
activity within these cells. In this regard, other groups have shown
that survival of different tumor cells depends on GSK-3b activity
trough a NF-kB-dependent pathway [7,43,44].
There is mounting evidence that neural stem cells can be
transformed into cancer stem cells and give rise to malignant
gliomas by escaping the mechanisms that control proliferation and
programmed differentiation [45,46,47]. Several data implicate
glioma stem cells in tumor maintenance and therapeutic resistance
[48,49,50], in consequence the discovery of putative brain tumor
stem cells identifies a new cellular target that might be susceptible
to novel treatments. Our results suggest that, in addition to have
an inhibitory effect upon the bulk of glioblastomas, TDZD-8 could
also inhibit cancer stem cell growth. Treatment with TDZD-8
resulted in an inhibition of neurosphere formation in culture.
TDZD-8 inhibited the proliferation and expansion of these
neurospheres and hampered their capacity of self-renewal. One
feature that contributes to the ability of a stem cell to survive is its
inherent resistance to drugs; in this regard our results are
particularly important since they suggest that TDZD-8 could
reduce the tumor-initiating cells. Our results provide compelling
evidence that TDZD-8 is able to both inhibit the bulk of the
tumor, characterized by actively cycling cells, and to hinder the
growth of neural stem cells characterized by a low rate of division.
In summary, we have presented here the first evidence that
TDZD-8 inhibits gliomagenesis and targets glioma stem-like cells
and thus may hold promise for treatment of human gliomas.
Materials and Methods
Animal Experiments
Adult male C57BL/6 mice (n=10 per group) were anaesthe-
tized by intraperitoneal injection of ketamine (60 mg/Kg) and
medetomidine (0.125 mg/Kg) and positioned in a stereotaxic
apparatus (Kopf Instruments, CA). To establish intracranial
tumors GL261 cells (125,000 cells) were implanted unilaterally
into the right hemisphere using the following coordinates from
Bregma: posterior 21.06 mm; lateral 3 mm and a depth of 3 mm,
according to the atlas of Paxinos and Franklin [51]. The mice were
then housed individually to recover. One day after implantation of
GL261 cells, two groups of mice were injected daily intraperito-
neally with 5 mg/Kg of TDZD-8 (Sigma) or DMSO (control
group) during 22 days. In other group of animals, treatment with
TDZD-8 was started 6 days after implantation of GL261 cells,
during 7 days. All procedures with animals were specifically
approved by the ‘Ethics Committee for Animal Experimentation’
of the Instituto de Investigaciones Biomedicas (CSIC-UAM),
permit number PN 2007/108, and carried out in accordance with
the protocols issued which followed National (normative 1201/
2005) and International recommendations (normative 86/609
from the European Communities Council). Special care was taken
to minimize animal suffering.
Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) was performed using an
MRI scanner (Bruker PharmaScan 7.0T, 16 cm; Bruker Medical
Gmbh, Ettlingen, Germany). Mice brain MRI was performed with
a 90 mm gradient insert and a concentrical 38 mm birdcage
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resonator, using Paravision v4.0 software (Bruker Medical Gmbh,
Ettlingen, Germany) as implemented in a Hewlett-Packard
console, operating on a Linux platform. MRI examinations used
adult male C57BL/6 mice (n$10 per group) anaesthetized
through a plastic mask with 2% isofluorane in 99.9% O2. Animals
were allowed to breath spontaneously during the experiment and
were placed in a heated cradle to maintain the core body
temperature at approx. 37uC. The physiological state of the
animal was monitored throughout MRI acquisition through the
respiratory rate using a Biotrig physiological monitor (Brucker).
Gadolinium-DTPA-enhanced T1-weighted spin-echo images were
acquired at 8, 10, 13 and 20 days after injection with a Rapid
Acquisition with Relaxation Enhancement (RARE) [52] sequence
in axial orientations (TR: 350 ms, TE: 10.6 ms, averages: 4, FOV:
2.30 cm, acquisition matrix: 2566256, slice thickness: 1.00 mm,
number of slices: 16). The in vivo spectroscopy protocol acquired
two 3x3x3 mm voxels in the striatal area, using a Point-Resolved
Spatially Spectroscopy (PRESS) [53] protocol, combined with
VAPOR water suppression, [54](TR: 3000 ms, TE: 35 ms,
averages: 128). Tumor area was calculated from T1-weighted
images using Image J Software. Tumor volume was estimated
from the summation of tumor areas on each slice, multiplied by
slice thickness. Average lesion volume was calculated for each
condition.
Histology and Immunohistochemistry
Brains were dissected and embedded in paraffin. Sections of
10 mm thickness were prepared and stained with haematoxylin
and eosin. Paraffin embedded sections, were also used for
detecting proliferation and apoptosis in tumors. First, sections
were deparaffinized in xylene and rehydrated in graded concen-
trations of ethanol. Endogenous peroxidase activity was blocked by
incubation in H2O2 and after several rinses in PBS, antigen
retrieval was performed by microwaving slides in citrate buffer.
Once non-specific binding sites were blocked for 1 hour at room
temperature, sections were incubated in humid chamber at 4uC
overnight with anti-active caspase-3 (1:200, R&D Systems) and
anti-PCNA (1:50, Signet Laboratories). After several rinses,
sections were incubated for 1 h with a biotinylated secondary
antibody and finally processed following the avidin-biotin protocol
(Vectastain ABC kit; Vector Laboratories). Tissues were mounted
onto gelatin-coated slides, dehydrated, cleared in xylene, and
mounted with DePeX (Serva, Heidelberg, Germany). The slides
were examined under a Zeiss (Oberkochen, Germany) Axiophot
microscope, equipped with an Olympus Optical (Tokyo, Japan)
DP-50 digital camera, and a Leica (Nussloch, Germany) MZ6
modular stereomicroscope. For the quantification of active
caspase-3 and PCNA expression, the number of positive cells
was quantified in 20 random fields at x400 magnification. Data
were expressed as mean 6 SD positive cells/field.
Cell culture and treatment
GL261 murine glioblastoma cells were obtained from the NCI-
Frederick Cancer Research Tumor Repository (Frederick, MD)
and propagated in RPMI medium with 10% fetal bovine serum as
described [55]. A172 and U373 human glioblastoma cell lines
were obtained from Dr. Manuel Guzman (Complutense Univer-
sity, Madrid, Spain) and propagated in DMEM with 10% FBS.
On attaining semiconfluence, and based in dose-response analysis
(see Fig. S2), cells were treated with 20 mM TDZD-8, a dose
widely used in the literature [18,56], for different time intervals.
Following treatment cells were processed for western blot and
immunocytochemical analysis.
For neurosphere formation GL261 cells were plated and grown
in regular medium (RPMI, 10% FBS, glutamine, gentamicine and
fungizone). Two days after plating, supernatant was collected and
replated in a defined serum-free tumor sphere medium formed by
Ham’s F-12/Dulbecco’s modified Eagle’s medium (1:1) supple-
mented with B27 (Invitrogen, Carlsbad, CA), 20 ng/ml epidermal
growth factor (EGF, Peprotech, EC) and 20 ng/ml fibroblast
growth factor (FGF, Peprotech, EC). After 1 week in culture some
primary neurosphere cultures were treated with TDZD-8 (10 mM)
for another 1 week. These primary neurospheres were then
dissociated, and 50,000 cells/ml were replated in proliferative
conditions, in the absence or presence of TDZD-8, for another 7 or
14 days to score the number of secondary neurospheres generated.
For self-renewing experiments, primary neurospheres were dissoci-
ated and plated at a density of 2,000 cells/ml for another 7 or 14
days in proliferative medium containing or not TDZD-8. These
assays were repeated at least three times in triplicate.
Proliferation assays
The effect of TDZD-8 on cell proliferation was determined
using the non-radioactive BrdU-based cell proliferation assay
(Roche) according to the manufacturer’s protocol. Cells were
seeded in triplicate onto 96-well plates at a density of 2,000 cells/
well. After 24 h of growth, cells were treated with 20 mM TDZD-
8, 16 h later 10 mM BrdU was added and cells were cultured for
another 16 h. BrdU incorporation into the DNA was determined
by measuring the absorbance at both 370 and 492 nm on an
ELISA plate reader.
Cell viability was measured using the MTT assay (Roche
Diagnostic, GmbH), based on the ability of viable cells to reduce
yellow MTT to blue formazan. Briefly, cells were cultured in 96-
well microlitre plates for various periods of time in the presence or
absence of 20 mM TDZD-8, then cells were incubated with MTT
(0.5 mg/ml, 4 h) and subsequently solubilized in 10% SDS/0.01
M HCl for 12 h in the dark. The extent of reduction of MTT was
quantified by absorbance measurement at 550 nm according to
the manufacturer’s protocol.
Immunoblot analysis
Cultured cells, both adherent and floating cancer stem cells, were
harvested and lysed in ice-cold RIPA buffer and equal quantities of
total protein were separated by 10% SDS-PAGE. After electro-
phoresis, proteins were transferred to nitrocellulose membranes
(Protran, Whatman, Dassel, Germany) and blots were probed with
the indicated primary antibodies, as previously described [57]. The
antibodies used were the following: rabbit polyclonal anti-p-ERK1/
2 (1:1000, Cell Signaling), rabbit polyclonal anti-ERK1/2 (Cell
Signaling), rabbit polyclonal anti-p90RSK (1:1000, Cell Signaling),
rabbit polyclonal anti-p-GSK-3b (1:500, Cell Signaling), mouse
monoclonal anti-GSK-3b (1:250, BD Transduction), rabbit poly-
clonal anti-EGR-1 (1:1000, Santa Cruz Biotechnology), rabbit
polyclonal anti-p21 (1:1000, Abcam), rabbit polyclonal anti-
Musashi 1 (1:1000, Abcam), rabbit polyclonal anti-Oct-4 (1:500,
Santa Cruz Biotechnology), rabbit polyclonal anti-Nestin (1:2000;
kindly provided by Dr. M. Vallejo, Instituto de Investigaciones
Biome´dicas, Madrid, Spain), and mouse monoclonal anti-a-tubulin
(1:5000, Sigma). Secondary peroxidase-conjugated donkey anti-
rabbit and rabbit anti-mouse antibodies were from Amersham
Biosciences (GE Healthcare, Buckinghamshire, England) and
Jackson Immunoresearch, respectively.
Immunocytochemical staining
At the end of the treatment period the cultures, grown on glass
cover-slips in 24-well cell culture plates, were washed with PBS
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and fixed for 30 min with 4% paraformaldehyde at 25uC and
permeabilized with 0.1% Triton X-100 for 30 min at 37uC. After
1 h incubation with the corresponding primary antibody: anti-
active caspase-3 (1:500, R&D Systems) cells were washed with PBS
and incubated with an Alexa-labeled secondary antibody (Invitro-
gen, San Diego, CA) for 45 min at 37uC. Images were acquired
using a Radiance 2100 confocal microscope (Bio-Rad, Hercules,
CA), with a 350 nm diode laser to excite DAPI (4,6,diamidino-2-
phenylindole) and a 488-Argon laser to excite Alexa 488. Confocal
microscope settings were adjusted to produce the optimum signal-
to-noise ratio. To compare fluorescence signals from different
preparations, settings were fixed for all samples within the same
analysis.
Determination of apoptotic cells
To calculate the extend of cell death, cells were treated or not
with TDZD-8 and TUNEL analysis were performed following the
manufacturer’s recommendations. Caspase-3 activation was
analyzed by immunofluorescence analysis using a specific anti-
active caspase-3 antibody. Some cultures were treated with the
caspase inhibitor z-VAD-fmk.
Transient transfections
For transient transfection experiments, semi-confluent GL261
cells were transfected with the 3xNFtk-luc reporter plasmid as
previously described [58]. Forty-eight hours after transfection, cells
were harvested for luciferase and-b-galactosidase (to determine
transfection efficiency) activities by using a reporter assay system
(Promega, Madison, WI). Each transient transfection experiment
was repeated at least three times in triplicate.
Statistics
Other than the survival experiments, Student’s test was used to
analyze statistical differences between the different groups.
Survival curves were plotted with Kaplan-Meier method and
survival for the two groups of animals was studied using log-rank
test. Differences were considered statistically significant at p,0.05.
Supporting Information
Figure S1 Effects of TDZD-8 administered after tumor is
established. Representative T1 magnetic resonance imaging (MRI)
pictures obtained from mice treated with TDZD-8 from day 6
after GL261 cells injection. T1-weighted imaging was performed
at 7 Tesla as described in Materials and Methods. The arrow
indicates the day the treatment was initiated.
Found at: doi:10.1371/journal.pone.0013879.s001 (1.16 MB TIF)
Figure S2 Cell viability in TDZD-8-treated cells. GL261
glioblastoma cells were incubated with various concentrations
of TDZD-8 and viability was assessed by the MTT assay, as
indicated in Materials and Methods. Values are the means 6 SD
of at least three different experiments.
Found at: doi:10.1371/journal.pone.0013879.s002 (0.07 MB TIF)
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